Skip to content

Acquisitions at other companies

CVS Health logo
CVS HealthCVS
$5M-75.0%
UnitedHealth Group logo
UnitedHealth GroupUNH
$0-100%
Astrana Health logo
Astrana HealthASTH
$51K-99.8%
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
$42.2M+525%
Elevance Health logo
Elevance HealthELV
-$5M-25.0%
Cencora logo
CencoraCOR
$4.71B+19.6%

Other financials

Income statement

See full
Revenue$496.2M+2.6%
Gross profit$83.8M-18.2%
Operating income-$10.6M-553%
Net income-$26.6M+58.8%
EPS (diluted)-$0.24+61.9%

Balance sheet

See full
Cash & equivalents$142.0M-42.4%
Total debt$985.4M+13.3%
Total equity$396.4M-57.6%
Total assets$1.9B-29.2%

Cash flow

See full
Operating cash flow-$984.0K-122%

Valuation

See full
Market cap$565.78M-47.9%
Enterprise value$1.41B-17.6%
P/S0.3×-0.2×

Profitability

See full
Gross margin20.2%+4.9pp
Operating margin-22.2%-23.5pp
Net margin-26.3%-33.2pp
FCF margin-9.7%

Returns & leverage

See full
Return on equity-74.6%-90.1pp
Debt / equity2.5×+1.6×
Current ratio1.3×+0.3×

Where this comes from

Reported directly by Evolent Health, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireBusinessesGross.

The official record: Evolent Health, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evolent Health, Inc.'s acquisitions.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Evolent Health, Inc.'s acquisitions?
Evolent Health, Inc. (EVH) reported acquisitions of $0 in Q1 2026.
How has Evolent Health, Inc.'s acquisitions changed year-over-year?
Evolent Health, Inc.'s acquisitions decreased by 100.0% year-over-year, from $4.5M to $0.
What is the long-term trend for Evolent Health, Inc.'s acquisitions?
Over 3 years (2021 to 2025), Evolent Health, Inc.'s acquisitions has grown at a 5.4% compound annual growth rate (CAGR), from $49.01M to $57.45M.
What does acquisitions mean?
Cash paid for business acquisitions net of cash acquired in the target company — the primary M&A cash flow line.